Porous Polymeric Microparticles as an Oral Drug Platform for Effective Ulcerative Colitis Treatment
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved..
Porous microparticles (MPs) have been regarded as a promising vehicle for drug delivery. Herein, porous MPs and their counterparts (nonporous MPs) were produced by a conventional emulsion-solvent evaporation method in the presence and absence of ammonium bicarbonate, and curcumin was encapsulated into these MPs during the preparation process. The obtained MPs possessed desirable diameters of around 1.2 μm and negative zeta potentials of approximately -28 mV. It was found that the release rate of curcumin was remarkably increased with the introduction of pores in MPs. Furthermore, orally administered porous MPs achieved statistically significantly better therapeutic outcomes against ulcerative colitis mouse model induced by dextran sulfate sodium, in comparison to nonporous MPs. These findings confirmed that porous MPs could be served as a promising platform for the treatment of ulcerative colitis via oral route.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
Journal of pharmaceutical sciences - 108(2019), 7 vom: 13. Juli, Seite 2238-2242 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Xin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.07.2020 Date Revised 27.07.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xphs.2019.02.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294051503 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294051503 | ||
| 003 | DE-627 | ||
| 005 | 20231225080647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xphs.2019.02.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0980.xml |
| 035 | |a (DE-627)NLM294051503 | ||
| 035 | |a (NLM)30779888 | ||
| 035 | |a (PII)S0022-3549(19)30085-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Xin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Porous Polymeric Microparticles as an Oral Drug Platform for Effective Ulcerative Colitis Treatment |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2020 | ||
| 500 | |a Date Revised 27.07.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Porous microparticles (MPs) have been regarded as a promising vehicle for drug delivery. Herein, porous MPs and their counterparts (nonporous MPs) were produced by a conventional emulsion-solvent evaporation method in the presence and absence of ammonium bicarbonate, and curcumin was encapsulated into these MPs during the preparation process. The obtained MPs possessed desirable diameters of around 1.2 μm and negative zeta potentials of approximately -28 mV. It was found that the release rate of curcumin was remarkably increased with the introduction of pores in MPs. Furthermore, orally administered porous MPs achieved statistically significantly better therapeutic outcomes against ulcerative colitis mouse model induced by dextran sulfate sodium, in comparison to nonporous MPs. These findings confirmed that porous MPs could be served as a promising platform for the treatment of ulcerative colitis via oral route | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a oral administration | |
| 650 | 4 | |a porous microparticle | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a ulcerative colitis | |
| 650 | 7 | |a Bicarbonates |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a ammonium bicarbonate |2 NLM | |
| 650 | 7 | |a 45JP4345C9 |2 NLM | |
| 650 | 7 | |a Dextran Sulfate |2 NLM | |
| 650 | 7 | |a 9042-14-2 |2 NLM | |
| 650 | 7 | |a Curcumin |2 NLM | |
| 650 | 7 | |a IT942ZTH98 |2 NLM | |
| 700 | 1 | |a Chen, Qiubing |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Ya |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yamei |e verfasserin |4 aut | |
| 700 | 1 | |a Gou, Shuangquan |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Bo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical sciences |d 1961 |g 108(2019), 7 vom: 13. Juli, Seite 2238-2242 |w (DE-627)NLM000006394 |x 1520-6017 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2019 |g number:7 |g day:13 |g month:07 |g pages:2238-2242 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xphs.2019.02.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2019 |e 7 |b 13 |c 07 |h 2238-2242 | ||